208 results on '"Nogova L"'
Search Results
2. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
3. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential
4. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
5. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
6. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
7. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
8. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis
9. P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases
10. KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors
11. The fading relevance of the quantity of brain metastases in patients with non-small cell lung cancer
12. Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases
13. RADIOMICS FOR THE NON-INVASIVE ASSESSMENT OF THE PDL-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES
14. Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors
15. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
16. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
17. The biological effect of small-scale ROS1 aberrations: An in silico analysis
18. Small-scale ROS1 aberrations: Functional impact and therapeutic potential
19. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort
20. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
21. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
22. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
23. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
24. 1374P Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
25. 1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
26. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
27. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors
28. SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
29. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data
30. Small Cell Lung Cancer - Filling the gap between science and patients
31. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup
32. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
33. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
34. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
35. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability
36. Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway
37. OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients
38. Genomic and clinical characterization of non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
39. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
40. FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC
41. Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)
42. Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients
43. Pharmacokinetics of nintedanib in combination with everolimus in patients with solid tumors - Results from the phase I BARIS trial
44. FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress)
45. BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer
46. Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression
47. Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations
48. Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway
49. NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers
50. EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.